Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 8.4% – Still a Buy?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) were up 8.4% on Thursday. The stock traded as high as $4.02 and last traded at $4.0550. 19,711,231 shares changed hands during mid-day trading, an increase of 3% from the average session volume of 19,182,031 shares. The stock had previously closed at $3.74.

Analyst Ratings Changes

A number of research firms have issued reports on RXRX. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Morgan Stanley set a $5.30 price target on shares of Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 29th. Two research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $8.06.

Recursion Pharmaceuticals Trading Up 13.0%

The company has a market cap of $2.26 billion, a PE ratio of -4.05 and a beta of 1.04. The business has a 50 day simple moving average of $3.61 and a two-hundred day simple moving average of $3.41. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.01). The business had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%. During the same quarter last year, the business earned ($0.41) EPS. On average, analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer directly owned 2,072,890 shares of the company’s stock, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, October 6th. The shares were sold at an average price of $4.84, for a total value of $242,000.00. Following the completion of the sale, the director owned 6,108,287 shares of the company’s stock, valued at $29,564,109.08. This trade represents a 0.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 157,408 shares of company stock worth $643,576. 6.65% of the stock is owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of RXRX. Ascent Wealth Partners LLC boosted its holdings in shares of Recursion Pharmaceuticals by 11.8% in the 1st quarter. Ascent Wealth Partners LLC now owns 28,081 shares of the company’s stock valued at $86,000 after purchasing an additional 2,974 shares during the last quarter. Cherry Creek Investment Advisors Inc. increased its holdings in shares of Recursion Pharmaceuticals by 5.8% during the 1st quarter. Cherry Creek Investment Advisors Inc. now owns 70,536 shares of the company’s stock worth $217,000 after buying an additional 3,859 shares during the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Recursion Pharmaceuticals by 33.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 16,832 shares of the company’s stock worth $52,000 after buying an additional 4,199 shares during the last quarter. Sequoia Financial Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 51.5% in the 1st quarter. Sequoia Financial Advisors LLC now owns 15,162 shares of the company’s stock worth $47,000 after buying an additional 5,156 shares during the period. Finally, Axxcess Wealth Management LLC raised its position in shares of Recursion Pharmaceuticals by 16.6% in the 1st quarter. Axxcess Wealth Management LLC now owns 37,516 shares of the company’s stock worth $115,000 after buying an additional 5,338 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc is a clinical-stage biotechnology company that uses biology, chemistry, automation and machine learning to discover and develop new medicines. The company’s technology platform is designed to generate and analyze large volumes of biological and chemical data, helping researchers identify potential drug candidates and better understand disease mechanisms.

Recursion has focused its research and development activities on areas including oncology, rare diseases and neuroscience.